# Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm

> **NCT06863662** · PHASE3 · COMPLETED · sponsor: **Laboratorios Silanes S.A. de C.V.** · enrollment: 136 (actual)

## Conditions studied

- Acute Low-back Pain
- Muscle Spasm; Back Pain

## Interventions

- **DRUG:** Etoricoxib + Tizanidine fixed dose
- **DRUG:** Etoricoxib fixed dose

## Key facts

- **NCT ID:** NCT06863662
- **Lead sponsor:** Laboratorios Silanes S.A. de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-18
- **Primary completion:** 2025-09-26
- **Final completion:** 2025-12-01
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06863662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06863662, "Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06863662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*